Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs PubMatic Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while PubMatic Inc trades at $13.52 (market cap $635.81M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 12.6× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | PUBM | |
|---|---|---|
Market Cap | $8.04B | $635.81M |
Sector | Health | Technology |
52-Week High | $339.75 | $13.83 |
52-Week Low | $241.71 | $6.28 |
Enterprise Value | $7.85B | $533.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
PubMatic trades at $13.57, up 0.15% with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations despite a net loss, with revenue of $282.93M in 2025 and a gross margin of 63.22%. Recent news highlights partnerships expanding AI-driven ad tech in CTV and international markets, supporting growth initiatives.
Outlook is mixed with strong analyst buy ratings (50%) and a $17.00 consensus target offering 25% upside, but profitability concerns persist with negative net margins and high P/E of 132. Key risks include competitive pressures and reliance on digital ad spending cycles, requiring monitoring of earnings turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
